NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress

Overview

Journal Antioxid Redox Signal

Specialty Endocrinology

Date 2014 Feb 12

PMID 24512192

Citations 35

Authors

Becky A Diebold

Susan M E Smith

Yang Li

J David Lambeth

Affiliations

Soon will be listed here.

Abstract

Significance: NOX2 is important for host defense, and yet is implicated in a large number of diseases in which inflammation plays a role in pathogenesis. These include acute and chronic lung inflammatory diseases, stroke, traumatic brain injury, and neurodegenerative diseases, including Alzheimer's and Parkinson's Diseases.

Recent Advances: Recent drug development programs have targeted several NOX isoforms that are implicated in a variety of diseases. The focus has been primarily on NOX4 and NOX1 rather than on NOX2, due, in part, to concerns about possible immunosuppressive side effects. Nevertheless, NOX2 clearly contributes to the pathogenesis of many inflammatory diseases, and its inhibition is predicted to provide a novel therapeutic approach.

Critical Issues: Possible side effects that might arise from targeting NOX2 are discussed, including the possibility that such inhibition will contribute to increased infections and/or autoimmune disorders. The state of the field with regard to existing NOX2 inhibitors and targeted development of novel inhibitors is also summarized.

Future Directions: NOX2 inhibitors show particular promise for the treatment of inflammatory diseases, both acute and chronic. Theoretical side effects include pro-inflammatory and autoimmune complications and should be considered in any therapeutic program, but in our opinion, available data do not indicate that they are sufficiently likely to eliminate NOX2 as a drug target, particularly when weighed against the seriousness of many NOX2-related indications. Model studies demonstrating efficacy with minimal side effects are needed to encourage future development of NOX2 inhibitors as therapeutic agents.

Citing Articles

Quercetin Mitigates Lysophosphatidylcholine (LPC)-Induced Neutrophil Extracellular Traps (NETs) Formation through Inhibiting the P2X7R/P38MAPK/NOX2 Pathway.

Liu S, Wang Y, Ying L, Li H, Zhang K, Liang N Int J Mol Sci. 2024; 25(17).

PMID: 39273358 PMC: 11395007. DOI: 10.3390/ijms25179411.

Ribociclib leverages phosphodiesterase 4 inhibition in the treatment of neutrophilic inflammation and acute respiratory distress syndrome.

Chen P, Chen S, Chen Y, Wang Y, Lin C, Chen C J Adv Res. 2024; 62:229-243.

PMID: 38548264 PMC: 11331181. DOI: 10.1016/j.jare.2024.03.019.

Structure of human phagocyte NADPH oxidase in the activated state.

Liu X, Shi Y, Liu R, Song K, Chen L Nature. 2024; 627(8002):189-195.

PMID: 38355798 DOI: 10.1038/s41586-024-07056-1.

Cardiac endothelial ischemia/reperfusion injury-derived protein damage-associated molecular patterns disrupt the integrity of the endothelial barrier.

Kumphune S, Seenak P, Paiyabhrom N, Songjang W, Pankhong P, Jumroon N Heliyon. 2024; 10(2):e24600.

PMID: 38312663 PMC: 10835233. DOI: 10.1016/j.heliyon.2024.e24600.

Novel NADPH Oxidase-2 Inhibitors as Potential Anti-Inflammatory and Neuroprotective Agents.

Juric M, Rawat V, Amaradhi R, Zielonka J, Ganesh T Antioxidants (Basel). 2023; 12(9).

PMID: 37759963 PMC: 10525516. DOI: 10.3390/antiox12091660.

References

Csanyi G, Cifuentes-Pagano E, Al Ghouleh I, Ranayhossaini D, Egana L, Lopes L . Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. Free Radic Biol Med. 2011; 51(6):1116-25. PMC: 3204933. DOI: 10.1016/j.freeradbiomed.2011.04.025. View

Harper R, Xu C, Eiserich J, Chen Y, Kao C, Thai P . Differential regulation of dual NADPH oxidases/peroxidases, Duox1 and Duox2, by Th1 and Th2 cytokines in respiratory tract epithelium. FEBS Lett. 2005; 579(21):4911-7. DOI: 10.1016/j.febslet.2005.08.002. View

Feng Y, Forgac M . Inhibition of vacuolar H(+)-ATPase by disulfide bond formation between cysteine 254 and cysteine 532 in subunit A. J Biol Chem. 1994; 269(18):13224-30. View

Sanchez G, Pedrozo Z, Domenech R, Hidalgo C, Donoso P . Tachycardia increases NADPH oxidase activity and RyR2 S-glutathionylation in ventricular muscle. J Mol Cell Cardiol. 2005; 39(6):982-91. DOI: 10.1016/j.yjmcc.2005.08.010. View

Stefanska J, Sarniak A, Wlodarczyk A, Sokolowska M, Doniec Z, Bialasiewicz P . Hydrogen peroxide and nitrite reduction in exhaled breath condensate of COPD patients. Pulm Pharmacol Ther. 2012; 25(5):343-8. DOI: 10.1016/j.pupt.2012.06.001. View

Sutcliffe A, Hollins F, Gomez E, Saunders R, Doe C, Cooke M . Increased nicotinamide adenine dinucleotide phosphate oxidase 4 expression mediates intrinsic airway smooth muscle hypercontractility in asthma. Am J Respir Crit Care Med. 2011; 185(3):267-74. PMC: 3402550. DOI: 10.1164/rccm.201107-1281OC. View

Lopez A, Mathers C . Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol. 2006; 100(5-6):481-99. DOI: 10.1179/136485906X97417. View

Taur Y, Frishman W . The cardiac ryanodine receptor (RyR2) and its role in heart disease. Cardiol Rev. 2005; 13(3):142-6. DOI: 10.1097/01.crd.0000128709.84812.86. View

Sauaia A, Moore F, Moore E, Moser K, Brennan R, Read R . Epidemiology of trauma deaths: a reassessment. J Trauma. 1995; 38(2):185-93. DOI: 10.1097/00005373-199502000-00006. View

10.

DAddio S, Prudhomme R . Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Deliv Rev. 2011; 63(6):417-26. DOI: 10.1016/j.addr.2011.04.005. View

11.

Schiavone S, Sorce S, Dubois-Dauphin M, Jaquet V, Colaianna M, Zotti M . Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats. Biol Psychiatry. 2009; 66(4):384-92. DOI: 10.1016/j.biopsych.2009.04.033. View

12.

Ikai T, Akao Y, Nakagawa Y, Ohguchi K, Sakai Y, Nozawa Y . Magnolol-induced apoptosis is mediated via the intrinsic pathway with release of AIF from mitochondria in U937 cells. Biol Pharm Bull. 2006; 29(12):2498-501. DOI: 10.1248/bpb.29.2498. View

13.

Bulut M, Savas H, Altindag A, Virit O, Dalkilic A . Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia. World J Biol Psychiatry. 2009; 10(4 Pt 2):626-8. DOI: 10.1080/15622970903144004. View

14.

Liu Y, Hernandez-Ochoa E, Randall W, Schneider M . NOX2-dependent ROS is required for HDAC5 nuclear efflux and contributes to HDAC4 nuclear efflux during intense repetitive activity of fast skeletal muscle fibers. Am J Physiol Cell Physiol. 2012; 303(3):C334-47. PMC: 3423023. DOI: 10.1152/ajpcell.00152.2012. View

15.

Lam G, Huang J, Brumell J . The many roles of NOX2 NADPH oxidase-derived ROS in immunity. Semin Immunopathol. 2010; 32(4):415-30. DOI: 10.1007/s00281-010-0221-0. View

16.

Do K, Trabesinger A, Lauer C, Dydak U, Hell D, Holsboer F . Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000; 12(10):3721-8. DOI: 10.1046/j.1460-9568.2000.00229.x. View

17.

Hooper N . Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein. Biochem Soc Trans. 2005; 33(Pt 2):335-8. DOI: 10.1042/BST0330335. View

18.

Surace M, Block M . Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cell Mol Life Sci. 2012; 69(14):2409-27. PMC: 3677079. DOI: 10.1007/s00018-012-1015-4. View

19.

Judkins C, Diep H, Broughton B, Mast A, Hooker E, Miller A . Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/- mice. Am J Physiol Heart Circ Physiol. 2009; 298(1):H24-32. DOI: 10.1152/ajpheart.00799.2009. View

20.

Tian N, Moore R, Phillips W, Lin L, Braddy S, Pryor J . NADPH oxidase contributes to renal damage and dysfunction in Dahl salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol. 2008; 295(6):R1858-65. PMC: 2685289. DOI: 10.1152/ajpregu.90650.2008. View